Return to content in this issue


Selective Response to Omalizumab in a Patient With Concomitant ncMCAS and POTS: What Does it Teach us About the Underlying Disease?

Kacar M, Denman S, Savic S

Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, UK

J Investig Allergol Clin Immunol 2018; Vol 28(4) : 261-263
doi: 10.18176/jiaci.0251

Key words: Nonclonal mast cell activation syndrome, Postural orthostatic tachycardia syndrome, Omalizumab